AEON BIOPHARMA, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.54 USD | +0.65% |
|
-8.33% | -78.61% |
| May. 09 | AEON Biopharma, Inc. Provides Update on Development Pipeline | CI |
| May. 03 | US Equity Markets Close Higher Friday Following Weak Jobs Report | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | - | 267.5 | 59.34 | - | - |
| Enterprise Value (EV) 1 | - | 267.5 | 59.34 | 59.34 | 59.34 |
| P/E ratio | -26.4 x | - | - | - | - |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | - | 37,160 | 38,783 | - | - |
| Reference price 2 | 10.05 | 7.200 | 1.530 | 1.530 | 1.530 |
| Announcement Date | 3/10/23 | 3/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -0.086 | -102.4 | -41.58 | -42.81 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income | -52.56 | - | - | - | - |
| Net margin | - | - | - | - | - |
| EPS | -0.3800 | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/10/23 | 3/29/24 | - | - | - |
1USD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | 55.24 | -34.73 | -10.38 | -8.511 | -9.997 | -9.766 | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - |
| Net income | -15.38 | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - |
| EPS | -0.1100 | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/18/23 | 11/13/23 | 3/29/24 | 5/14/24 | - | - | - | - | - |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 3/10/23 | 3/29/24 | - | - | - |
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.53
USD
Average target price
6
USD
Spread / Average Target
+292.16%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -78.61% | 59.34M | |
| +9.76% | 115B | |
| +11.91% | 106B | |
| -2.77% | 21.96B | |
| -14.11% | 21.87B | |
| -5.29% | 19.21B | |
| -3.20% | 18.08B | |
| -38.57% | 17.71B | |
| +6.41% | 14.32B | |
| +35.38% | 12.42B |
- Stock Market
- Equities
- AEON Stock
- Financials AEON Biopharma, Inc.
